NGNE Share Price Performance
US$17.38
-1.04 (-5.65%)
Price US$17.38
Share Pricen/a
Here's Why We're Not Too Worried About Neurogene's (NASDAQ:NGNE) Cash Burn Situation
Dec 31
Neurogene Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
NGNE Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Neurogene Inc. Key Details
About NGNE
- Founded
- 2018
- Employees
- 107
- CEO
- WebsiteView website
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
